Charles Mills

Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA.

Be The Match is a non-profit organization that connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant. The private company is based in Minneapolis. The American company operates the most diverse registry in the world, which includes both adult donors willing to donate to a stranger in need and stored cord blood units. Be The Match provides patients and their families one-on-one support, education, and guidance before, during, and after transplant. Amy L. Ronneberg has been the CEO of the company since 2013.

Be The Match Foundation provides bone marrow and cord blood transplant services. The non-profit company is based in Minneapolis, MN.

Part of The Marrow Foundation, National Marrow Donor Program provides treatments for those facing life-threatening blood cancers. The private company is based in Minneapolis, MN.

KeraLink International, Inc. operates as a non-governmental network of eye and tissue banks. It also provides ocular tissues used in transplant surgeries. The company was founded in 1962 and is headquartered in Baltimore, MD.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.